BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
22 nov. 2021 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...
ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
01 juil. 2021 16h15 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy...
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
16 juin 2021 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has accepted the regulatory...
BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
06 mai 2020 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
27 juin 2019 16h15 HE
|
BioCryst Pharmaceuticals, Inc.
—Data expected in Q4 2019— —BCX9930 showed high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— RESEARCH TRIANGLE PARK, N.C., June 27, 2019 (GLOBE...
BioCryst to Present at Barclays Global Healthcare Conference
28 févr. 2019 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare...
BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4
18 févr. 2019 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2018...
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
20 nov. 2018 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. ...
BioCryst Reports Third Quarter 2018 Financial Results
06 nov. 2018 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced...